Pharma Stocks
-
GSK’s $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal
This article first appeared on GuruFocus. GSK Plc (NYSE:GSK) is leaning harder into the United States, with outgoing CEO Emma…
Read More » -
Piramal Pharma Sees 12.33% Surge in Open Interest Amid Increased Trading Activity
Piramal Pharma Ltd has seen a significant rise in open interest, reaching 11,026 contracts, alongside a trading volume of 8,228…
Read More » -
These 4 Measures Indicate That Sotac Pharmaceuticals (NSE:SOTAC) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway’s Charlie Munger, Li Lu, makes no bones about it when he says…
Read More » -
Pfizer Stock (PFE) Climbs after Pricing Deal with Trump, 3-Year Exemption from Pharma Tariffs
The shares of Pfizer (PFE) pumped up on Tuesday afternoon after the American pharmaceutical giant agreed to an arrangement with…
Read More » -
Tonix Pharma Appoints Market Access Head After FDA Fibromyalgia Drug Win
Tonix Pharmaceuticals (Nasdaq: TNXP) has appointed Ganesh Kamath as Head of Market…
Read More » -
Bliss GVS Pharma Hits Day High with Strong 13.52% Surge
Bliss GVS Pharma has experienced notable trading activity, gaining 13.52% on September 30, 2025, and reaching an intraday high of…
Read More » -
Trump built a tariff wall, Indian pharma found a European gate – Stock Insights News
The Indian pharma industry is expanding its presence in the European market with a number of acquisitions in this region…
Read More » -
US market today: Wall street rebounds after 1 week of losses; tech and pharma stocks gain
US stocks opened higher on Monday, clawing back some losses from last week, with investors eyeing a key economic report…
Read More » -
FTSE 100 Up Nearly 0.5%; Pharma, Mining Stocks Rise
(RTTNews) – The U.K. market is up firmly in positive territory on Monday, supported by gains in pharma and mining…
Read More » -
Is Crinetics Pharmaceuticals Stock a Buy?
The FDA just handed this clinical-stage biotech its golden ticket — but at a $4.3 billion valuation, the market’s already…
Read More »